BioCentury | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
BioCentury | Jun 9, 2014
Clinical News

3PO: Phase I started

Advanced Cancer Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV PFK-158, with a starting dose of 24 mg/m 2, in up to 48 patients with advanced solid tumors, including melanoma and...
BioCentury | Oct 22, 2012
Emerging Company Profile

Sprint: Quick start in cancer

Sprint Bioscience AB is leveraging its founders' expertise in fragment-based drug discovery and structural biology to generate leads against novel cancer metabolism and autophagy targets. The biotech hopes to out-license its therapeutics when the molecules...
BioCentury | Apr 19, 2012
Distillery Therapeutics

Indication: Cancer

...Publication and contact information Cancer Prostate cancer 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) Cell culture and mouse studies suggest inhibiting PFKFB4...
...treat prostate cancer. In a panel of prostate cancer cell lines, small interfering RNA targeting PFKFB4...
...with control siRNA. In a xenograft mouse model of prostate cancer, small hairpin RNA targeting PFKFB4...
BioCentury | Jul 2, 2010
Financial News

Advanced Cancer Therapeutics raises $10 million

Advanced Cancer Therapeutics LLC (Louisville, Ky.) raised $10 million in seed financing from undisclosed high net-worth individuals and institutions in Kentucky. The company has three lead programs to treat cancer: small molecule inhibitors for 6-phosphofructo-2-kinase...
BioCentury | Mar 10, 2008
Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer Therapeutics received an exclusive, worldwide license from the university to develop and market 3PO and related compounds to treat cancer. The inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 ( PFKFB3 ) is in preclinical testing to treat leukemia...
Items per page:
1 - 7 of 7